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The lancet has been instrumental in publishing 
studies on renal sympathetic denervation (rDN) in 
hypertension and, accordingly, has strongly contrib-
uted to the promotion of this technology to be applied 
in patients with apparent treatment-resistant hyper-
tension (1–3). However, with the recent publication 
of the Symplicity HTN-3 study in the USa (4), the 
world has seemingly overnight become in doubt 
whether rDN lowers blood pressure at all. an Editor 
of another distinguished journal (5) published his 
reflections and stated that the Symplicity HTN-3 
results came as a shock to the world; a single but 
large and properly designed prospective randomized 
clinical trial could on its own neutralize hundreds of 
mostly observational studies, case reports and other 
enthusiastic publications emphasizing the amazing 
effects of rDN, not only in patients with resistant 
hypertension, but also in a host of other diseases and 
conditions.
The initial enthusiasm followed by the setback of 
rDN can probably be summarized by a handful of 
reflections and explanations: (i) the role of the sympa-
thetic system in the pathophysiology of hypertension 
is substantiated by a wealth of experimental and 
clinical arguments (6–12). On this background, 
enthusiasm surged when an intervention in this 
system seemed to drastically lower blood pressure. 
(ii) Market-driven industry took control and exerted an 
unprecedented influence on the medical community. 
(iii) Subsequently, pitfalls in apparent treatment- 
resistant hypertensive patients, which are simple but 
have been well known for decades, were suddenly 
forgotten including well described phenomena such 
as the placebo effect, regression to the mean, poor 
drug adherence (13–15) and the Hawthorne effect 
(http://en.wikipedia.org/wiki/Hawthorne_Works).
The history of the rise and fall of rDN – a 
perceived miracle in the treatment for millions of 
hypertensive patients – deserves a more in-depth 
analysis. The first and for a long time the only 
prospective randomized clinical trial in this field, 
the Symplicity HTN-2 study (2) was monitored by 
ardian (Medtronic), who collected and processed 
the data (2). Usually, when such a task is given to 
industry, all measures are taken to secure confidence 
and show that the trials are prospective, randomized 
and double-blinded (16–18). However, in this case, 
everything was open, making the trial particularly 
vulnerable to patients, physicians and sponsor-related 
biases (19). Shun-Shin et al. (20) in a recent editorial 
nicely stated that “measurement of a noisy variable 
by un-blinded optimistic staff is a known recipe for 
calamitous exaggeration”. it is unfortunate that the 
selection of patients enrolled in Symplicity HTN-2 
and the evaluation of efficacy were based on office 
rather than ambulatory blood pressure measurement 
(aBPM), which is state-of-the art (21), particularly 
in resistant hypertension (22). aBPM reduces 
observer bias and measurement error, minimizes the 
white-coat effect and has greater reproducibility, and 
therefore provides a better estimate of a patient’s 
usual blood pressure and cardiovascular prognosis 
(23,24). Notwithstanding the well-known, major 
contribution of poor drug adherence to apparently 
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resistant hypertension (13–15), drug adherence was 
not monitored, either at baseline or during follow- 
up. This made the study vulnerable to the Hawthorne 
effect (http://en.wikipedia.org/wiki/Hawthorne_Works, 
see Figure 1), i.e. patients changing behaviour – in 
this case starting taking their drugs as prescribed – in 
response to the intervention and massive attention 
devoted to them. The lack of blood pressure decrease 
in the control group also raises concerns. One would 
indeed suspect that patients in the control group had 
not taken their medications properly, in order to keep 
their blood pressure at a higher level that made them 
eligible to cross over to the rDN group (25,26). 
Finally, the placebo effect and regression to the mean 
must also be taken into account. Simply by recruiting 
patients with the highest blood pressures at the out-
set would yield more blood pressure decrease at 
follow-up. it is noteworthy that the placebo effect is 
small using aBPM (21,27); however, ambulatory 
blood pressures remain as sensitive to the Hawthorne 
effect as office blood pressure.
Despite the major limitations and potential biases 
of Symplicity HTN-2, a small open study with a sub-
optimal design including only 106 patients followed 
up for 6 months, rDN was adopted in hundreds of 
centres worldwide. Medtronic inc.® (Minneapolis, 
Minnesota) paid $800 million to purchase ardian® 
(Mountain view, California), the company that had 
developed the technology (5), and more than 10 
companies developed their own rDN systems, five 
of which obtained the CE mark. The procedure 
was quickly adopted in Germany, and later in 
Switzerland, Sweden and the Netherlands. While 
rDN remained an investigational procedure in the 
USa, at least 8000 (28), possibly 15,000–20,000 
procedures were performed in Europe and in the rest 
of the world in less than 4 years, most of them using 
the ardian–Medtronic® catheter. it may be hypoth-
esized that the massive incomes generated by selling 
the Symplicity catheter to enthusiastic Europeans 
contributed to the expenses of the Symplicity HTN-3 
study (4), required by the Food and Drug adminis-
tration before approval of rDN in the USa. in Sym-
plicity HTN-3 (4), blinding of patients through the 
use of a sham procedure and wider use of aBPM 
balanced and limited the differential impact of the 
Hawthorne, white coat, placebo and regression to the 
mean effects in both treatment arms, disclosing to 
the world the true size of the blood pressure decrease 
attributable to rDN, at least in patients meeting the 
Symplicity criteria; it was less than 2 mmHg systolic 
based on aBPM.
For all the aforementioned reasons, and in view 
of the complexity and multifactorial character of 
hypertension, the failure of rDN to normalize or 
substantially reduce blood pressure in all patients 
with apparently resistant hypertension was a reason-
able working hypothesis for us, even before the 
Medtronic announcement that Symplicity HTN-3 
had failed to meet its primary endpoint (http://www.
tctmd.com/show.aspx?id  123265). We (29–31) and 
others (19,25) had predicted that the true effect of 
rDN might have been overestimated and may con-
siderably shrink in properly designed studies (19), 
and that “one size may not fit all” (26). in particular, 
in preliminary analysis of the European Network 
COordinating research on renal Denervation 
(ENCOreD) network (32), we were struck by the 
imbalance between the 17.6 mmHg decreases in 
office blood pressure, vs. only 5.9 mmHg for 24-h 
ambulatory blood pressure.
When we set out to investigate the effects of rDN 
in one of the centres with the longest experience in 
conducting randomized clinical trials in Europe (33), 
we had thus clearly in mind the limitations of previ-
ous studies. We needed a simple and practical way to 
deal with pitfalls in the recruitment of patients with 
resistant hypertension into a study protocol. after 
Figure 1. Hawthorne was an electrical power plant in Chicago (http://en.wikipedia.org/wiki/Hawthorne_Works). Some investigators 
discovered in the 1920s that the employees worked much harder if lights were turned brighter. But the workers had been informed of the 
experiment and it was after a while understood that they did not respond to the lights being improved, but simply changed their behaviour 
because they were under observation. in no other field of medicine is this phenomenon more powerful than in hypertension research. 
Simply teaching people to take their own blood pressure (49) is changing their behaviour and improving their drug adherence. it is thus 
no surprise that apparent treatment-resistant hypertensive people who have a mixed motivation for taking their drugs, to a certain degree 
explaining why they appear as drug-resistant, start taking their drugs following renal sympathetic denervation (rDN), with a subsequent 
dramatic, but largely non-specific blood pressure fall.
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extensively ruling out secondary hypertension, and 
improving drug treatment as well as possible bias 
based on clinical judgements in the run-in phase, 
patients had to qualify for the rDN protocols by 
having elevated daytime ambulatory blood pressures 
after witnessed intake of their prescribed blood pres-
sure medication (30). This was a convenient way to 
identify the true treatment-resistant hypertensive 
patients and to exclude patients with white coat 
hypertension or those non-adherent patients whose 
blood pressure normalized after witnessed drug 
intake. Meanwhile, a leading hypertension centre in 
Germany (34) published a small but well docu-
mented series of patients whose blood pressure 
remained unchanged after rDN. For many hyper-
tension experts in Europe, this was a clear sign of 
what was to come. We were thus not surprised when 
we found no change in either office or ambulatory 
blood pressures following rDN, first in an open 
series of six patients (30), later followed by a ran-
domized study – the Oslo-rDN trial (35). Patients 
who were randomly assigned to further improvement 
of drug treatment guided by non-invasive haemody-
namic monitoring had normalized blood pressures. 
in contrast, patients exposed to rDN experienced 
only a small and probably partly placebo-induced fall 
in office and ambulatory blood pressures (Table i). 
The decreases averaged 20 mmHg more for office 
and 9 mmHg more for ambulatory systolic blood 
pressure in the haemodynamically guided drug treat-
ment group compared with the rDN group.
in the absence of solid evidence of efficacy, how 
can we explain the uncontrolled deployment of rDN 
in Europe and worldwide (with the notable exception 
of the USa where rDN remained an investigational 
procedure)? Of course, publications of the Symplicity 
studies and of multiple observational studies, and 
enthusiastic editorials and reviews in The Lancet 
(1–3) and other top-ranking journals such as Circulation 
(36) and the Journal of the American College of 
Cardiology (37) had a substantial impact, and the 
lack of strict rules for introduction of device-based 
therapies in Europe facilitated the large-scale imple-
mentation of the technique. However, this phenom-
enon would have remained limited without huge 
promotion by device-producing industry. Probably 
never before has industry launched a stronger cam-
paign to market a new technology. a multitude of 
national and international advisory boards organized 
educational meetings, developed a website (www.
poweroverpressure.com) and produced guidelines. 
Medical journals were swamped by reviews and 
meta-analyses showing the powerful blood pressure 
lowering effects as recorded in observational studies 
and in the single available randomized study, Sym-
plicity HTN-2. Comments pointing out the defects 
and inconsistencies in such meta-analysis encoun-
tered a great delay in being published (38). Physi-
cians were invited to training sessions and the 
sponsor promoted rDN in large as well as in small 
hospitals, public and private clinics and facilitated 
with all means the recruitment of patients to physi-
cians and centres who would perform the procedure. 
Many never questioned whether rDN should be 
implemented, but when it should start in an institu-
tion. The purpose was to disseminate the enthusiasm 
for rDN from the technically oriented invasive radi-
ologists and cardiologists who usually had little inter-
est or experience in the treatment of hypertension to 
the “hypertension establishment”. The European 
Society of Hypertension issued specific guidelines 
(39,40), but maintained reservations that more data 
Table i. Characteristics and results of three prospective and randomized studies of blood pressure lowering 
effects of renal sympathetic denervation (rDN) with Symplicity catheters.
variable Symplicity HTN-2 Oslo rDN Symplicity HTN-3
Year 2010 2014 2014
Design Open Open SHaM single-blind
Drug adherence Patient diary Witnessed intake Patient diary
rDN Control rDN Control rDN Control
No. of patients 52 54 9 10 364 171
No. of drugs 5.2 5.3 5.1 5.0 5.1 5.2
intervention rDN No active rDN Drug adjustment rDN No active
Office SBP
Baseline, mmHg 178 178 156 160 180 180
Δ FU – 6 month, mmHg –32  1 –8 –28 –14.13 –11.74
Δ rDN – control, mmHg –33  20 –2.39
ambulatory SBP
Baseline, mmHg ?* ?* 152 152 159 160
Δ FU – 6 month, mmHg –11 –3 –10 –19 –6.75 –4.79
Δ rDN – control, mmHg –8**  9 –1.96
 SBP, systolic blood pressure; FU, follow-up; 6 month, 6-month follow-up; –, Δ rDN control in favour of 
renal denervation group, , Δ in favour of control group; ?*, baseline ambulatory blood pressure values 
were not given in this study.  8** results is given just for the difference between 20 patients in renal 
denervation group and 25 patients in control group.
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was needed, and eventually it had to be proved that 
rDN would lower morbidity and mortality before 
being generally accepted in the treatment of true or 
apparent treatment-resistant hypertension.
Unfortunately, the most enthusiastic proponents 
of rDN do not seem to have fully accepted the les-
sons of Symplicity HTN-3. in the aftermath of Sym-
plicity HTN-3, a campaign has been set up to criticize 
the study because of including inexperienced inves-
tigators, and enrolling too many african american 
patients (28,41). it has been suggested that the lack 
of demonstrated efficacy of rDN in Symplicity 
HTN-3 may be due to lack of statistical power or 
even to chance (28), or that the trial was well con-
ceived but not rigorously executed (41). Further-
more, the Symplicity HTN-3 results are diluted by 
non-scientific comparisons with the Medtronic® reg-
istry (42), which is hampered by all the weaknesses 
touched upon in this commentary, and even more as 
it is a pure industry-ran activity. Finally, while rDN 
will not become available in the USa, and ongoing 
research in asia was stopped, Medtronic and other 
companies continued making their catheters avail-
able for clinical use in Europe and did not restrain 
from heavily promoting the technique, for example 
at the Euro PCr conference in Paris in May 2014 
(www.medscape.com/author/shelley-wood).
Does the failure of Symplicity HTN-3 mean the 
end of rDN? Not necessarily. indeed, as already 
mentioned, rDN is based on a solid rationale sub-
stantiated by over 50 years of meticulous research of 
the sympathetic nervous system and its involvement 
in the pathophysiology of hypertension (6–12). Fur-
thermore, it has been shown in cohorts recruited 
from the 1930s (The effect of progressive sympath-
ectomy on blood pressure, Walter Bradford Cannon 
1931, http://www.ncbi.nlm.nih.gov/pubmed/2204236) 
until the 1950s (43,44) that abdominal sympathec-
tomy associated to splanchnicectomy is effective in 
the treatment of severe hypertension. Finally, many 
centres report major responses to rDN in a minority 
of patients (30,32,35). accordingly, research should 
go on to determine the minority of patients who are 
true responders to rDN, and identify predictors of 
effective rDN (Figure 2). The European Network 
for Coordinating renal Denervation (ENCOreD) 
has been set up to include thousands of patients in 
randomized protocols, observational studies and reg-
istries independent of industry. Some early results 
(32,45) from this joint effort have already been pub-
lished and suggest that it may be worthwhile search-
ing for potential predictors of response to rDN.
Still, before going ahead, we have to draw the 
lessons of the rDN story. The wisdom hereof is 
firstly that no new bright idea can suddenly appear 
and resolve the problem of hypertension – or even 
resistant hypertension – as a whole. Previous knowl-
edge has been building up through clever research 
by generations of investigators and hypertension 
cannot be resolved overnight. Hypertension is too 
complex and multifactorial, and the size of the prob-
lem so extensive that nobody in this field should let 
things like the commercial marketing of rDN hap-
pen in the way it did. We must make sure that rDN 
is beneficial and does no harm. Many patients have 
probably undergone unneeded procedures. By a 
careful estimate, 20 000 renal arteries have been 
exposed to ablation in people with hypertension and 
an increasing number of cases of renal artery steno-
sis after rDN are reported (46). very recent news 
along these lines is that in Germany the insurance 
companies have terminated their coverage. it remains 
to be seen whether the negative news that rDN is 
not for most people will reach Time Magazine (47) 
and Der Spiegel (48). 
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